主页 > 生命科学 >
【技术产业】【专题】 2007年第三季度各大制药公
（编译至美联社等境外媒体）
受肿瘤药物Avastin强劲销售的带动，基因泰克公司（Genetech）在2007年第三季度盈利达到6.85亿美元，合每股收益64美分，相比去年同期的5.68亿美元，合每股收益53美分，上涨了21%。总收入达到29.1亿美元，相比去年同期的23.8亿美元上涨了22%。若不计入特殊项目开支，也就是花费9.19亿美元收购Tanox公司，该公司当季盈利为7.78亿美元，合每股收益73美分，较去年同期上涨22%。
这一结果高于华尔街29.3亿美元收入、每股72美分的普遍市场预期。
在本周一的媒体发布会上，公司主管通报了一系列的销售和研发进展的情况。其中,肺癌、乳腺癌和结肠癌治疗药物Avastin（贝伐单抗）在该季度的销售额达到了5.97亿美元，同比增长了37%,比分析师预计的还要多出几百万美元。
同时，合作伙伴罗氏公司已经获得了Avastin在欧洲治疗特定肺癌的批准。而基因泰克公司也正向FDA申报Avastin用于治疗转移性乳癌。另外，Avastin用于外科手术切除肿瘤后的辅助治疗效果评价也正处于临床试验之中。一旦成功，将使得基因泰克公司能够分享价值50亿美元的外科手术切除肿瘤后的处方药市场。
但是，来自Cowen & Co公司的生物技术分析师Eric Schmidt认为基因泰克公司过于倚重Avastin了，因为在它的货架上除了Avastin能够保持30%的年增长率之外，其他产品的表现并不抢眼。他还认为尽管Avastin目前的销售势头不错，但能否延续还要看临床试验的结果。
其他方面，公司第二大药物，用于治疗类风湿性关节炎和非霍奇金(淋巴瘤)的Rituxan（利妥昔单抗，美罗华），该季度销售额达到5.72亿美元，同比上涨12%。肿瘤药Herceptin(赫赛汀，曲妥珠单抗)的销售额达3.2亿美元，上涨6%；黄斑性病变治疗药物lucentis（雷尼株单抗）于2006年7月批准上市之后，销售额达到1.98亿美元，上涨29%；哮喘治疗药物Xolair（奥马珠单抗）销售额达1.21亿美元，上涨13%。
此外，基因泰克公司在近一年时间里投入5.787亿美元进行研发，增长38%。公司预计全年盈利在每股2.85~2.95美元之间，而市场预计为2.95美元。
公布该季度财报之后，基因泰克公司股价上涨近1%，即25美分，达77.50美元，成为市值最大的生物技术公司，达816亿美元。
相比之下，销售额最大的生物技术公司安进在本季度的表现不尽如人意，股价下跌50美分至57.67美元每股，市值缩水至627美元。（丁香园编译）
基因泰克公司和安进公司在第三季度的股价走势比较
screen.width-333)this.width=screen.width-333" width=584 height=291 title="Click to view full Amgen和Genetech股价对比（第三季度）.jpg (584 X 291)" border=0 align=absmiddle> 好论题，顶一个先，期待ing。 不错,很好的帖子 雅培公司第三季度财报
Abbott Laboratories 3Q Profit Flat
Wednesday October 17, 9:54 am ET
By Ashley M. Heher, AP Business Writer
Abbott Laboratories Posts Flat 3rd-Quarter Profit Due to Hefty Costs, Guidant Unit Buyout
CHICAGO (AP) -- Health care products company Abbott Laboratories reported virtually flat third-quarter profit Wednesday as costs from the buyout of Guidant Corp.'s vascular stent business offset a 14 percent rise in revenue.
ADVERTISEMENT
click here
The company earned $717 million, or 46 cents per share, compared with $715.8 million, or 46 cents per share, during the same period last year. Excluding one-time items, the company said it earned 67 cents per share in the quarter that ended Sept. 30.
Revenue rose 14 percent to $6.38 billion from $5.57 billion a year ago, largely driven by strong global pharmaceutical sales, which climbed nearly 20 percent. The company's top-selling drug Humira, which treats Crohn's disease among other ailments, saw worldwide sales grow nearly 49 percent to $803 million.
Meanwhile, medical product sales grew 12 percent and nutritional sales grew about 4 percent.
The results beat consensus estimates of analysts polled by Thomson Financial, who expected adjusted profit of 66 cents per share on revenue of $6.24 billion. Thomson estimates typically exclude one-time items.
Abbott's shares advanced 77 cents, or about 1.5 percent, to $52.74 in morning trading.
"Abbott's strong performance this quarter was again balanced across our major broad-based businesses," Chief Executive Miles White said in a statement. "We expect this momentum to continue."
North Chicago-based Abbott also raised the low-end of its full-year guidance, forecasting profit between $2.82 and $2.84 per share, up from previous estimates of $2.80 to $2.84. The outlook excludes about 44 cents per share in costs, including charges from its 2006 acquisition of a Guidant unit from Boston Scientific Corp. as well as cost-cutting initiatives and inventory writedowns.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-03-28 17:14
医学,生命科学网